Quantum BioPharma Ltd. Clarifies Misinformation Regarding Name Change and RTO
TL;DR
Quantum BioPharma clarifies no name change or RTO with Unbuzzd, maintaining its strategic investments and royalties, offering investors clear advantages in biopharmaceutical innovations.
Quantum BioPharma detailed its financial and operational separateness from Unbuzzd, including shareholdings, royalty agreements, and a $1.3 million loan, amidst social media misinformation.
Quantum BioPharma's commitment to treating neurodegenerative and metabolic disorders through innovative biotech solutions promises a healthier future for affected individuals worldwide.
Quantum BioPharma, holding significant stakes in Unbuzzd, navigates through misinformation while advancing in biopharmaceutical research and strategic investments.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) has taken steps to clarify widespread misinformation circulating on social media and stock trading platforms about a purported name change and reverse takeover (RTO) involving Unbuzzd Wellness Inc. The company confirmed that it has not changed its name to Unbuzzd and is not engaged in an RTO transaction with the wellness company. This clarification comes in the wake of confusion following a press release dated May 29, 2025.
Despite the clarification, Quantum BioPharma's relationship with Unbuzzd is significant. Quantum is the largest shareholder and debt holder of Unbuzzd, holding 200 million shares, a 7% royalty agreement on revenue up to $250 million, and a warrant that could increase its stake to 25%. Additionally, Quantum has provided Unbuzzd with a $1.3 million loan at a 10% interest rate over three years. Unbuzzd, under the leadership of former Coca-Cola executive John Duffy and former Celsius Holdings CEO Gerry David, is gearing up for a potential initial public offering (IPO), with MNP LLP conducting PCAOB audits in preparation.
In other developments, Quantum BioPharma announced a pending $20,930 debt settlement with two vendors, expected to be finalized in early June. This news underscores the company's ongoing financial and strategic maneuvers within the biopharmaceutical sector. Quantum BioPharma specializes in developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with a portfolio that includes innovative drug candidates at various stages of development.
The clarification from Quantum BioPharma is crucial for investors and the market, as it dispels rumors that could have led to unnecessary volatility in the company's stock. By maintaining transparency about its operations and financial dealings, Quantum BioPharma reinforces its commitment to corporate governance and investor relations, ensuring that stakeholders have accurate information for making informed decisions.
Curated from InvestorBrandNetwork (IBN)
